193 related articles for article (PubMed ID: 11802205)
21. Oncogenic transformation and inhibition of adipocytic conversion of preadipocytes by TLS/FUS-CHOP type II chimeric protein.
Kuroda M; Ishida T; Takanashi M; Satoh M; Machinami R; Watanabe T
Am J Pathol; 1997 Sep; 151(3):735-44. PubMed ID: 9284822
[TBL] [Abstract][Full Text] [Related]
22. Monoclonality of multifocal myxoid liposarcoma: confirmation by analysis of TLS-CHOP or EWS-CHOP rearrangements.
Antonescu CR; Elahi A; Healey JH; Brennan MF; Lui MY; Lewis J; Jhanwar SC; Woodruff JM; Ladanyi M
Clin Cancer Res; 2000 Jul; 6(7):2788-93. PubMed ID: 10914725
[TBL] [Abstract][Full Text] [Related]
23. Characteristic sequence motifs at the breakpoints of the hybrid genes FUS/CHOP, EWS/CHOP and FUS/ERG in myxoid liposarcoma and acute myeloid leukemia.
Panagopoulos I; Lassen C; Isaksson M; Mitelman F; Mandahl N; Aman P
Oncogene; 1997 Sep; 15(11):1357-62. PubMed ID: 9315104
[TBL] [Abstract][Full Text] [Related]
24. Rearrangement of the transcription factor gene CHOP in myxoid liposarcomas with t(12;16)(q13;p11).
Aman P; Ron D; Mandahl N; Fioretos T; Heim S; Arheden K; Willén H; Rydholm A; Mitelman F
Genes Chromosomes Cancer; 1992 Nov; 5(4):278-85. PubMed ID: 1283316
[TBL] [Abstract][Full Text] [Related]
25. Detection of TLS/FUS-CHOP fusion transcripts in a case of oral liposarcoma.
Rivero ER; Mesquita RA; de Sousa SC; Nunes FD
Ann Diagn Pathol; 2006 Feb; 10(1):36-8. PubMed ID: 16414544
[TBL] [Abstract][Full Text] [Related]
26. Myxoid liposarcoma FUS-DDIT3 fusion oncogene induces C/EBP beta-mediated interleukin 6 expression.
Göransson M; Elias E; Ståhlberg A; Olofsson A; Andersson C; Aman P
Int J Cancer; 2005 Jul; 115(4):556-60. PubMed ID: 15688424
[TBL] [Abstract][Full Text] [Related]
27. A rare chimeric TLS/FUS-CHOP transcript in a patient with multiple liposarcomas: a case report.
Schneider-Stock R; Rys J; Walter H; Limon J; Iliszko M; Niezabitowski A; Roessner A
Cancer Genet Cytogenet; 1999 Jun; 111(2):130-3. PubMed ID: 10347549
[TBL] [Abstract][Full Text] [Related]
28. Liposarcoma initiated by FUS/TLS-CHOP: the FUS/TLS domain plays a critical role in the pathogenesis of liposarcoma.
Pérez-Losada J; Sánchez-Martín M; Rodríguez-García MA; Pérez-Mancera PA; Pintado B; Flores T; Battaner E; Sánchez-Garćia I
Oncogene; 2000 Dec; 19(52):6015-22. PubMed ID: 11146553
[TBL] [Abstract][Full Text] [Related]
29. The myxoid/round cell liposarcoma fusion oncogene FUS-DDIT3 and the normal DDIT3 induce a liposarcoma phenotype in transfected human fibrosarcoma cells.
Engström K; Willén H; Kåbjörn-Gustafsson C; Andersson C; Olsson M; Göransson M; Järnum S; Olofsson A; Warnhammar E; Aman P
Am J Pathol; 2006 May; 168(5):1642-53. PubMed ID: 16651630
[TBL] [Abstract][Full Text] [Related]
30. Myxoid liposarcoma with EWS-CHOP type 1 fusion gene.
Suzuki K; Matsui Y; Endo K; Kubo T; Hasegawa T; Kimura T; Ohtani O; Yasui N
Anticancer Res; 2010 Nov; 30(11):4679-83. PubMed ID: 21115923
[TBL] [Abstract][Full Text] [Related]
31. Genomic PCR detects tumor cells in peripheral blood from patients with myxoid liposarcoma.
Panagopoulos I; Aman P; Mertens F; Mandahl N; Rydholm A; Bauer HF; Mitelman F
Genes Chromosomes Cancer; 1996 Oct; 17(2):102-7. PubMed ID: 8913727
[TBL] [Abstract][Full Text] [Related]
32. Human translocation liposarcoma-CCAAT/enhancer binding protein (C/EBP) homologous protein (TLS-CHOP) oncoprotein prevents adipocyte differentiation by directly interfering with C/EBPbeta function.
Adelmant G; Gilbert JD; Freytag SO
J Biol Chem; 1998 Jun; 273(25):15574-81. PubMed ID: 9624148
[TBL] [Abstract][Full Text] [Related]
33. Primary retroperitoneal myxoid/round cell liposarcoma is a nonexisting disease: an immunohistochemical and molecular biological analysis.
de Vreeze RS; de Jong D; Tielen IH; Ruijter HJ; Nederlof PM; Haas RL; van Coevorden F
Mod Pathol; 2009 Feb; 22(2):223-31. PubMed ID: 18820664
[TBL] [Abstract][Full Text] [Related]
34. A novel oncogenic pathway by TLS-CHOP involving repression of MDA-7/IL-24 expression.
Oikawa K; Tanaka M; Itoh S; Takanashi M; Ozaki T; Muragaki Y; Kuroda M
Br J Cancer; 2012 Jun; 106(12):1976-9. PubMed ID: 22588557
[TBL] [Abstract][Full Text] [Related]
35. DDIT3/CHOP and the sarcoma fusion oncoprotein FUS-DDIT3/TLS-CHOP bind cyclin-dependent kinase 2.
Bento C; Andersson MK; Aman P
BMC Cell Biol; 2009 Dec; 10():89. PubMed ID: 20017906
[TBL] [Abstract][Full Text] [Related]
36. Myxoid liposarcoma confirmed by TLS/FUS-CHOP fusion transcripts.
Huang YL; Hong HS; Kuo TT; Chung CJ
Dermatol Surg; 2003 Sep; 29(9):980-1. PubMed ID: 12930346
[TBL] [Abstract][Full Text] [Related]
37. Abnormal expression of cell cycle regulators in FUS-CHOP carrying liposarcomas.
Olofsson A; Willén H; Göransson M; Engström K; Meis-Kindblom JM; Stenman G; Kindblom LG; Aman P
Int J Oncol; 2004 Nov; 25(5):1349-55. PubMed ID: 15492825
[TBL] [Abstract][Full Text] [Related]
38. TLS-CHOP represses miR-486 expression, inducing upregulation of a metastasis regulator PAI-1 in human myxoid liposarcoma.
Borjigin N; Ohno S; Wu W; Tanaka M; Suzuki R; Fujita K; Takanashi M; Oikawa K; Goto T; Motoi T; Kosaka T; Yamamoto K; Kuroda M
Biochem Biophys Res Commun; 2012 Oct; 427(2):355-60. PubMed ID: 22995304
[TBL] [Abstract][Full Text] [Related]
39. Myxoid liposarcoma with adipocytic maturation: detection of TLS/CHOP fusion gene transcript.
Nakanishi H; Araki N; Joyama S; Higuchi C; Mano M; Ishiguro S; Itoh K; Ueda T; Yoshikawa H
Diagn Mol Pathol; 2004 Jun; 13(2):92-6. PubMed ID: 15167010
[TBL] [Abstract][Full Text] [Related]
40. Fusion of the dominant negative transcription regulator CHOP with a novel gene FUS by translocation t(12;16) in malignant liposarcoma.
Rabbitts TH; Forster A; Larson R; Nathan P
Nat Genet; 1993 Jun; 4(2):175-80. PubMed ID: 7503811
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
